Our Science – Ambudkar Website
Suresh V. Ambudkar, Ph.D.
Selected Publications |
 |
| 1)
Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem. Pharmacol. 85: 325-34, 2013. [Journal] |
|
| 2)
Liu K, He J, Su X, Sim H, Xie J, Chen X, Wang F, Liang Y, Singh S, Sodani K, Talele TT, Ambudkar SV, Chen Z, Wu H, Fu L. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 132: 224-35, 2013. [Journal] |
|
| 3)
Duveau DY, Hu X, Walsh MJ, Shukla S, Skoumbourdis AP, Boxer MB, Ambudkar SV, Shen M, Thomas CJ. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorg. Med. Chem. Lett. 23: 682-6, 2013. [Journal] |
|
| 4)
Sen R, Natarajan K, Bhullar J, Shukla S, Fang H, Cai L, Chen Z, Ambudkar SV, Baer MR. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the multidrug resistance-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 11:: 2033-44, 2013. [Journal] |
|
| 5)
Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem. Pharmacol. 85: 514-24, 2013. [Journal] |
|
| 6)
Downes MT, Mehla J, Ananthaswamy N, Wakschlag A, Lamonde M, Dine E, Ambudkar SV, Golin J. The transmission interface of the Saccharomyces cerevisiae multidrug transporter Pdr5: Val-656 located in intracellular loop 2 plays a major role in drug resistance. Antimicrob. Agents Chemother. 57: 1025-34, 2013. [Journal] |
|
| 7)
Zhang DM, Shu C, Chen JJ, Sodani K, Wang J, Bhatnagar J, Lan P, Ruan ZX, Xiao ZJ, Ambudkar SV, Chen WM, Chen ZS, Ye WC. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol. Pharm. 9: 3147-59, 2012. [Journal] |
|
| 8)
Gupta V, Bhinge KN, Hosain SB, Xiong K, Gu X, Shi R, Ho MY, Khoo KH, Li SC, Li YT, Ambudkar SV, Jazwinski SM, Liu YY. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells. J. Biol. Chem. 287: 37195-205, 2012. [Journal] |
|
| 9)
Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin. Cancer Res. 18: 3197-206, 2012. [Journal] |
|
| 10)
Zhao X, Xie J, Chen X, Sim HM, Zhang X, Liang Y, Singh S, Talele TT, Sun Y, Ambudkar SV, Chen Z, Fu L. Neratinib (HKI-272) Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance in Vitro, in Vivo and ex Vivo. Mol Pharmacol. 82:: 47-58, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/4/2013.
